Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers Squibb Company Provides Update on Checkmate -651 Trial Evaluating Opdivo Plus Yervoy

07/16/2021 | 06:59am EDT

Bristol Myers Squibb announced an update on the Phase 3 CheckMate -651 trial comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Although Opdivo plus Yervoy showed a clear, positive trend towards overall survival (OS) in patients whose tumors express PD-L1 with a combined positive score (CPS) = 20, the study did not meet its primary endpoints. The safety profile of Opdivo and Yervoy in this trial was consistent with previously reported studies in solid tumors. Opdivo monotherapy previously demonstrated a survival benefit in adults with recurrent or metastatic SCCHN after platinum-based therapy in the CheckMate -141 trial. Based on these results, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved Opdivo for this indication in 2016. In addition, Opdivo plus Yervoy-based combinations have shown significant improvements in OS in six Phase 3 clinical trials in five different tumors to date: non-small cell lung cancer, metastatic melanoma, advanced renal cell carcinoma, malignant pleural mesothelioma and esophageal squamous cell carcinoma. Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -651 clinical trial. The company will complete a full evaluation of the data and work with investigators to share the results with the scientific community.


ę S&P Capital IQ 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
09/20BRISTOL MYERS SQUIBB : FDA Grants Bristol-Myers Squibb Priority Review for Metastatic Mela..
MT
09/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
BU
09/20Bristol Myers Squibb Announces FDA Accepts for Priority Review Biologics License Applic..
CI
09/20Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
DJ
09/17BRISTOL MYERS SQUIBB : Combination Therapy Gets EMA Committee's Backing for Treating Gastr..
MT
09/17BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherap..
BU
09/17Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo with Chemotherapy for Pa..
CI
09/17Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers
DJ
09/16Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Sinc..
DJ
09/16BRISTOL MYERS SQUIBB : Reports Data From Phase 3 Trial of Opdivo, Yervoy Combination
MT
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 378 M - -
Net income 2021 6 495 M - -
Net Debt 2021 28 289 M - -
P/E ratio 2021 21,0x
Yield 2021 3,24%
Capitalization 134 B 134 B -
EV / Sales 2021 3,49x
EV / Sales 2022 3,14x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 60,63 $
Average target price 75,39 $
Spread / Average Target 24,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-3.03%133 660
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972